ALLSTAR confirmed durable Durvalumab benefit while high-dose RT showed a thoracic-control signal
Durvalumab after CRT improved long-term outcomes in stage III NSCLC, while dose escalation above 66 Gy showed only exploratory intrathoracic benefit.
Tag
nsclc
Very late toxicities emerged more than a decade after stage I lung SBRT
Ten-year lung SBRT survivors developed rare airway, chest-wall and pericardial toxicities, while no local failures occurred beyond year 10.
Five-fraction SBRT showed encouraging early safety in frail stage III NSCLC
Sequential chemotherapy plus five-fraction SBRT produced 86.7% one-year local control with 7.7% acute grade 3 toxicity in STARLORD.
Single-fraction SABR matched multi-fraction outcomes in early-stage NSCLC
In 778 patients, single-fraction SABR showed similar local failure, survival and toxicity to three- or four-fraction treatment.
Personalized RT strategies are moving locally advanced NSCLC beyond the PACIFIC template
Modern LA-NSCLC RT is shifting toward selective escalation, de-escalation and organ sparing, increasingly guided by patient risk and tumor biology.
Aggressive concurrent hypofractionation increased fatal toxicity in unresectable stage II–III NSCLC
Across 26 studies, fatal toxicity clustered when BED10 >100 Gy was delivered to the whole tumor with concurrent platinum chemotherapy.
Bayesian heart-dose constraints improved cardiac risk selection in NSCLC
Personalized Bayesian heart-dose limits improved identification of NSCLC patients at low risk of treatment-related cardiac troponin elevation.
Chemotherapy-free RT plus durvalumab was feasible in PD-L1-high locally advanced NSCLC
Concurrent durvalumab with either 60 Gy/15 or 60 Gy/30 was feasible in a 24-patient phase I study without concurrent chemotherapy.
Sequential hypofractionation improved locoregional control in locally advanced NSCLC
Sequential 55 Gy in 20 fractions achieved 62% three-year locoregional control, outperforming conventionally fractionated sequential chemoradiotherapy without greater toxicity.
Daily low-dose cisplatin chemoradiotherapy remained feasible in older stage III NSCLC
Patients >70 receiving 66 Gy with daily low-dose cisplatin had survival and severe toxicity similar to younger patients in this retrospective cohort.
Heterogeneous EclipseRT plus PD-1 therapy was feasible in nine bulky NSCLC patients
EclipseRT plus PD-1 blockade produced five responses among nine bulky NSCLC patients without grade ≥3 treatment-related toxicity.
Iodine-125 brachytherapy preserved lung function in high-risk NSCLC patients
CT-guided iodine-125 implantation achieved 60.7% one-year response without grade ≥3 pneumonitis in patients with severe pulmonary dysfunction.
Three-cycle thoracic Quad Shot was feasible with concurrent systemic therapy in metastatic NSCLC
Three Quad Shot cycles caused limited high-grade toxicity, no systemic-therapy delays and frequent thoracic symptom improvement.
Mechanistic model predicted six-month lymphocyte depletion after lung SBRT
A circulation-based model predicted post-SBRT lymphocyte trajectories and linked a higher predicted lymphocyte nadir with better survival.
ELCC 2026 highlights expanding roles for radiotherapy across modern thoracic oncology
ELCC 2026 highlighted growing integration of SBRT and thoracic radiotherapy with targeted therapy, immunotherapy and biomarker-guided treatment selection.